

Scientific Publications and Articles

Spine.

First Author in published case series of Modic Therapy and 100 case series of Disc pain

Contributing author in publications on endoscopic discectomy and epiduroscopy with EuroPainClinic

Publications and in Press

1. Treatment of Discogenic Back Pain and Sciatica in daily practice: Report of 100 Sequential Cases of Interventional Back Pain Treatment with DISC-FX. A Hammond MD FRCP, C Hess, and C Oram. Pain News 1 September 2019 Vol 17 No 3
2. EQ 5-D As a suitable assessment of quality of Life after Epiduroscopy. Multicentre randomised double-blinded pilot study. Griger, M et al (in preparation)
3. Prophylactic and therapeutic activity of alkaline phosphatase in arthritic rats: single agent effects of alkaline phosphatase and synergistic effects in combination with methotrexate. Chandrupatla DMSH, Molthoff CFM, Ritesma IGR, Vos, R, Elsof E, Matsutama T, Low PS, Musters RJP, Hammond A, Windhorst AD, Lamertsma AA, van der Laken CJ, Braands R, Jansen G.
www.translationalres.com/inpress
4. Mini-micro discectomy by DISC-FX appears effective for chronic back and leg pain in daily clinical practice. Abstract No: WCMISST17-1024 For oral presentation at WCMISST Paris, May 2017.
5. Modic Antibiotic Spinal Therapy (MAST). Early experience in the use of antibiotics in Modic-related back pain (MRBP). A case report and prospective, open-label, observational study. JoOPM. 2016. 1(5). 3-12.
6. Rheumatoid Arthritis Patients With Inadequate Response to Oral MTX Maintain Satisfactory Disease Control and Durable Long-term Response When Switched to SC MTX. Accepted as poster for ACR, November 2014.
7. Access to the Next Wave of Biologic Therapies (Abatacept and Tocilizumab) for the Treatment of Rheumatoid Arthritis in England and Wales: Addressing Difficulties with the Current NICE Guidance (MTA195 and TA198). Yee Chiu, Andrew Ostor, Anthony Hammond, Katharina Sokoll, Marina Anderson, Maya Buch, Michael R Ehrenstein, Patrick Gordon, Sophia Steer, Ian N Bruce. Submitted. Clinical rheumatology
8. Rheumatoid Arthritis Patients With Inadequate Response to Oral Methotrexate Maintain Satisfactory Disease Control and Durable Long-term Response When Switched to Subcutaneous. Hammond, A , Bately B. Eular 2014 poster
9. Hylastan versus Steroid for Knee Osteoarthritis: Double-blind Randomized Trial. Lawrence Housman MD¹, Nebojsa Skrepnik MD, PhD¹, Nathan Wei MD, FACP, FACR², Thomas J Schnitzer MD, PhD³, David Waddell MD⁴, Charles Birbara MD⁵, Hasan Tahir BSc, MBBS, FRCP⁶, Nigel Arden MBBS, FRCP, MSc, MD⁷, Anthony Hammond MD, FRCP⁸, Phillippe Goupille MD⁹, Bernd-Jan Sanson MD, PhD¹⁰, Francois Bailleul MD¹⁰, Clare Elkins MS¹¹, Thierry Conrozier MD. Knee Surgery Sports Traumatology Arthroscopy. Published online 15th Feb 2013. DOI 10.1007/s00167-013-2438-7
10. Subcutaneous Methotrexate is More Efficacious and Better Tolerated Than Oral Methotrexate: The Experience of a Large Group of Patients in the Rheumatology Department of a

District General Hospital A. Liakos ,* , M. Batley , T. Hammond, A. Saha , P. Shrestha, A. Keough. Ann Rheum Dis 2012;71 (Suppl3):672

11. The Impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis. Campbell RCJ, Bately M, Hammond A, Ibrahim F, Kingsley G, Scott D. In submission 2011, Clinical Rheumatology.
12. The efficacy of Infliximab in sciatica induced by disc herniations located at L3/4 or L4/5: A small scale randomised controlled trial. Karpinnen J, Kothonen T, Hammond A, Bowman C, Malmivaara A, Veeger N, Sdeitsalo S and Hurri H. 2009 The Open Spine Journal. I, 9-13
13. Use of Parenteral Methotrexate significantly reduces the need for biologic therapy. Rheumatology 2007; 46 (1):i25 Use of Parenteral Methotrexate significantly reduces the need for biologic therapy (letter). Rheumatology. 47(2):222, 2008 Feb.
14. Strict adherence to BASDAI score may mislead the treatment decisions in patients with Ankylosing spondylitis. Arthritis Rheum September 2007, Volume 56.
15. Abatacept (ABA) provides sustained clinical benefit through 3 years in Rheumatoid Arthritis (RA) in patients (PTs) with inadequate responses to Methotrexate (MTX). Hammond A, Emery P, Aranda R, Becker J P, Zhou Y, Dougados M and Westhovens R. BSR 2007 Final abstract number: 53
16. Using the health Assessment Questionnaire to estimate preference-based single indices in patients with Rheumatoid Arthritis. Bansback N, Marra C, Tsuchiya A, Anis A, Guh D, Hammond A and Brazier J. 2007 Arthritis Care and research (manuscript ref ACR-06-0117) NB provenance of final publication uncertain.

Previously Published

1. The treatment of disc herniation-induced sciatica with Infliximab. One-year follow-up results of FIRST II, a randomized controlled trial. Korhonen T, Karpinnen J, Paimela L, Malmivaara A, Lindgren K-A, Bowman C, Hammond A, Kirkham B, Jarvinen S, Niinimäki J, Veeger N, Haapea M, Torkki M, Tervonene O, Seitsalo S and Hurri H. 2006. Spine 31: 2759-66.
2. Bansback N, Brennan A, Reynolds A, Conway P and Hammond T. 2001 In Rheumatoid arthritis (RA) Utility should be Calculated from EQ-5D Rather than SF-36 due to Floor Effects. Arthritis and Rheumatism, (S) abstract 209 ACR 2001.
3. Hammond A and Jeganathan N. 2001. Experience of anti-TNF treatment with Infliximab (Remicade) and Methotrexate in routine clinical practice over 40 weeks. Rheumatology 40: 149 (S1)
4. Hammond A and Jeganathan N. 2001. Hylan GF-20 in avoidance of knee surgery. Rheumatology 40: 299 (S1)
5. Peterson PL, Steer S, DeLord D, and Hammond A. 2001. Treatment of refractory orbital myositis with Infliximab (Remicade) a case report. Rheumatology 40: 346 (S1)
6. Monaghan J, Hammond A, Rodway A, Conry B and MacFarlane D. 2001. Identifying Patients at risk of Osteoporosis in General Practice. Osteoporosis International 12: S40 (S1)
7. Steer S, Monaghan J and Hammond A. 1999. Maidstone Osteoporosis Case Ascertainment Study: Discovering Unmet Need. 1999. Annals Rheum Diseases. 242. (S)
8. Donnelly, S., J.T. Bourne, D.A. Levinson, D.V. Doyle, and A Hammond. 1993. Grand Rounds in

Rheumatology: Amyloid arthritis associated with IgM kappa lymphoplasmacytoid lymphoma. British Journal of Rheumatology. 32: 1004 –1007

9. Spector TD, Woodward L, Hall GM, Hammond A, Williams A, Butler MG, James IT, Hart DJ, Thompson PW, Scott DL. 1992. Keratan sulphate in rheumatoid arthritis, osteoarthritis, and inflammatory diseases. Annals of the Rheumatic Diseases. 51(10):1134-7.

10. Hammond, A., W. Ollier, and MJ. Walport. 1992. Effects of C4 null alleles and homoduplications on quantitative expression of C4A and C4B. Clin. Exp. Immunol. 88:163-8.

11. Hammond, A., AC. Rudge, S. Loizou, SJ. Bowcock, and MJ. Walport. 1989. Reduced numbers of

CR1 on erythrocytes from patients with SLE and the antiphospholipid syndrome are associated with increased levels of anticardiolipin antibodies.

Arthritis and Rheumatism. 32: 259-264.

12. Walport, M.J., Hammond, A, Davies, K.A.A., Moldenuaer, F. 1989. Complement receptor type-1 and SLE. In: Proceedings of the Second International Conference on SLE.

Professional Postgraduate Services, Tokyo, 52-55.

13. Johnston, SRD, A. Hammond, L. Griffiths, R. Greenwood, and CRA. Clarke. 1989. Subarachnoid haemorrhage - can we do better?

Journal of the Royal Society of Medicine. 82:721-724.

14. Pozniak, A, and A. Hammond. 1983. A report on the use of trans-oesophageal pacing in a case of hypothermia. Brit Med J. 289: 1315.

15. Hammond A, Denton A, Ensor A, Scott DL, Doyle DV. 1992. Which clinical measurements

are suitable to follow-up ankylosing spondylitis?

British Journal of Rheumatology. 31:2 72 (S).

16. Hammond A and Doyle DV. 1992. Computers in medical audit: experience with the NE Thames Clinical Information System (CIS). British Journal of Rheumatology. 31:2 146 (S).

17. Woodward L, Spector TD, Hammond A, Hall GM, Williams A, Doyle DV, Scott D.L. 1991. Keratan Sulphate and the acute phase response. British Journal of Rheumatology. 30:2 236 (S).

18. Doyle DV and Hammond A. 1990. Rheumatology Clinical Referral Audit and General Practitioner Education Planning. British Journal of Rheumatology. 29:2 169 (S)

19. Hammond A, Loizou S, Cofiner C, Walport MJ. 1990. Anticardiolipin antibodies (ACA) may

be a common anti-erythrocyte autoantibody.

Clinical and Experimental Rheumatology. 8: 32B (S).

20. Hammond A, Rudge AC, Loizou S, Bowcock SJ, Walport MJ. 1988.

Anticardiolipin antibodies (ACA), complement, and erythrocyte complement receptor type 1 (CR1). British Journal of Rheumatology. 27:2 151 (S).

21. Hammond A and Walport MJ. 1988. C4A and C4B deposition on red cells from patients with SLE and normal controls. British Journal of Rheumatology. 27:2 40 (S).

Research related to MD thesis

Abnormalities of Immune Complex Processing in Systemic Lupus Erythematosus.

This 3-year laboratory research project was supported by an ARC Junior Research Fellowship and was undertaken at the Royal Postgraduate Medical School, Hammersmith Hospital under the supervision of Dr M J Walport. The Doctorate was awarded by the University of Edinburgh in October 1991. Dr Walport is now Professor, Sir Mark Walport the Chief Scientific Officer.

Commercial and Investigator Led Studies

At MTW, I employed 2 research nurses as well as leading the CLRN for Kent

1. REUMAP. Investigator led proof of concept study to investigate the role of bovine Alkaline Phosphatase in active RA. In collaboration with Alloksys Life Sciences.
2. OFA110635: A double-blind, randomized, placebo controlled, parallel group, multi-centre, phase III trial of Ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to Methotrexate therapy
3. MA21573: International Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an inadequate response to current non-biologic DMARD or Anti-TNF Therapy
4. Roche WA17047. A randomized phase 3 controlled double-blind parallel group multicentre study to evaluate the safety and efficacy of Rituximab in combination with MTX compared to MTX alone, in MTX-naïve patients with active RA
5. Roche WA18230 A randomized placebo controlled multi-centre phase 1/11 study of escalating single intravenous doses of Ocrelizumab in patients with moderate to severe RA receiving stable doses of MTX but with unsatisfactory clinical response.
6. BMS 101-102 A phase III multi-centre randomised double blind placebo controlled study to evaluate the efficacy and safety of BMS-188667 in combination with MTX alone in subjects with active RA and inadequate response to MTX
7. BMS Sub investigator. M101-064: A Phase 111 multi-centre open label study to evaluate the efficacy, tolerability and safety of Abatacept (BMS-188667) in subjects with active rheumatoid arthritis on background Non-biologic DMARDs who have an inadequate response to Anti-TNF therapy and have limited therapeutic options.
8. Sumitomo Sub investigator: ASPECTS: A phase 2 multi-centre, randomised, double blind, placebo controlled study evaluating the efficacy, safety and pharmacokinetics of two doses of a candidate disease modifying Anti-rheumatic drug (DMARD), (SMP-114 120mg and 240mg once daily), administered in combination with ongoing Methotrexate treatment in patients with active rheumatoid arthritis.
9. Investigator Led/Schering Plough. FIRST II. A randomized placebo-controlled, double-blinded study of ANTI-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade®) in sciatica
10. Genzyme: Lead Investigator: AVSOO103: A multi-centre parallel, double blind, blinded evaluator, randomized comparison of the efficacy and safety of an alternate Viscosupplement (AVS-beta) to Methylprednisolone acetate in patients with symptomatic osteoarthritis of the knee
11. SPIRES: Investigator Led Spinal interventions results study. A retrospective and prospective audit of patient-centred outcomes of spinal interventional treatments.
12. Protocol IM 101-102. A phase III, multi-centre, randomised, double-blind placebo-controlled study to evaluate the efficacy and safety of BMS 18867 in combination with Methotrexate vs Methotrexate alone in subjects with active rheumatoid arthritis and inadequate response to Methotrexate.
13. Protocol IM 101-100. A phase IIb, Multi-Centre, Randomised Double Blind, Placebo Controlled Study to evaluate the Safety and Clinical Efficacy of Two Different Doses of BMS 188667 administered intravenously to subjects with active Rheumatoid Arthritis while receiving Methotrexate: sponsored by BMS Ltd. Results published in NEJM.
14. CARDERA: a 2 year multi-centre study of multi-drug regime in early RA: Collaborator.

15. The Chantry Osteoporosis Project: to define the incidence of undiagnosed osteoporosis in a local General Practice: completed and reported in abstract.
16. A Double Blind, Randomised, Placebo-controlled, parallel Group Study to evaluate the safety and efficacy of Alefacept (LFA-3/IgG1 Fusion Protein) in subjects with active Rheumatoid Arthritis on Methotrexate therapy. Trial not proceeded recruitment completed elsewhere.
17. SF-36, DAS and EuroQuol 5-D: which is the optimal measure of cost-utility for TNF therapy in RA. Supported by Wyeth in collaboration with Dept Health Studies, Sheffield University.
18. A six month trial of Valdecoxib v. Diclofenac: sponsored by Searle Pharmaceuticals.
19. A long term randomised placebo controlled clinical trial to evaluate the disease modifying effect of Hyalgan in osteoarthritis of the knee. Sponsored by Fida SPA. Completed. Results published.
20. A six month comparative study of intra-articular Synvisc and steroid for OA of the knee. This study is of my own design, conducted in collaboration with Dr MacFarlane, Rheumatologist, Tunbridge Wells. Completed. Submitted in abstract but unpublished.
21. The efficacy of intravaginal oestrogen therapy in post menopausal osteoporosis. Sponsored by Galen Pharmaceuticals. Completed.
22. MOCAS. The Maidstone Hospital Osteoporosis Case Ascertainment Study. I designed this protocol to elucidate the extent of potentially treatable osteoporosis in the Maidstone Hospital. We have shown that of 1800 patients at risk of osteoporosis having contact with the Maidstone Hospital in one year, only 20% are under appropriate investigation or management. Results have been published in abstract.
23. Epidural steroid therapy in spinal pain. A retrospective audit of patient rated satisfaction amongst 50 treated cases. 70% of patients respond to simple epidural injection and 60% of these rate themselves as excellent or good after 6 months.
24. An eight week double blind randomised parallel group study to compare Naproxen 500 mg/Misoprostol 200 mcg BD with Naproxen 500 mg BD in patients with Rheumatoid Arthritis or osteoarthritis. Sponsored by Searle UK.
25. Double-blind randomised multi-centre clinical study to evaluate the efficacy and tolerability of Nimesulide vs Diclofenac in patients suffering with osteoarthritis. Sponsored by Helsinn UK/Charterhouse Health Services.
26. Arthrotec 75. Efficacy and safety in OA and RA. Sponsored by Searle UK.
27. A six month double blind randomised parallel group study to compare SC-58635 200 mg bid and Diclofenac 75 mg slow release bid for anti-arthritic efficacy, incidence of endoscopically detected gastroduodenal ulceration and tolerability in patients with rheumatoid arthritis. Sponsored by Searle UK. (Now marketed as Celecoxib).
28. Add Enbrel or Replace Methotrexate (ADORE) Study: A randomised study of the efficacy and safety of Enbrel (Etanercept) plus Methotrexate versus Enbrel alone in Patients with active Rheumatoid Arthritis despite current Methotrexate Therapy.

Invited articles and presentations

1. Hammond A and Doyle DV. 1992. Management protocols for osteoarthritis. Prescriber .32: 35-39. Hammond A. 1992. What the tests mean. Arthritis News. April 1992 et seq.
2. 1998. Etodolac; Waking up to Cox-2 Selectivity. Invited presentation at BSR.

Satellite Symposium, Monmouth Pharmaceuticals.

3. 2001. A Renaissance in Rheumatology. Invited presentation at BSR Satellite Symposium, Schering-Plough Pharmaceuticals. Edinburgh.
4. 2001. Anti-TNF therapy in RA: presentation to members of the House of Commons Science and Technology Select Committee.
5. 2001. Procurement of Anti-TNF therapy: Educational video produced for Wyeth Pharmaceuticals.
6. 2002. Hip Injection technique: Educational Video produced for Biogen Pharmaceutical.
7. 2004. Viscosupplementation: Experience from Clinical Practice. In
Visco-supplementation:
Evidence and Applications in Osteoarthritis. Invited presentation at BSR.
Satellite Symposium, Genzyme UK

Further invited National and International presentations include BSR satellite symposia, The Real Meeting, Barcelona 2010 and local and regional presentations, IDF Educational Meeting Barcelona 2011, BPS IPM SIG presentations on Percutaneous Disc Decompression and Cervical RF, Contributor to Map of Medicine and to NICE research development proposals for sciatica.

